Table 2. Stratified analyses of the ELAC2 Ser217Leu polymorphism on prostate cancer risk.

Variables	na	Cases/controls	Leu allele vs Ser allele		SL vs SS		LL vs SS		SL/LL vs SS
			OR (95% CI)	Pb	OR (95% CI)	Pb	OR (95% CI)	Pb	OR (95% CI)	Pb
Total	17	5476/6794	1.13 (1.03–1.24)c	0.019	1.21 (1.07–1.36)c	0.034	1.11 (0.93–1.31)	0.284	1.20 (1.07–1.35)c	0.025
Ethnicities
Caucasian	9	3318/3299	1.12 (1.00–1.25)c	0.045	1.18 (1.03–1.36)	0.097	1.15 (0.90–1.46)	0.110	1.18 (1.03–1.37)	0.054
Asian	4	814/950	2.09 (1.07–4.05)	0.134	2.37 (1.26–4.44)	0.206	1.10 (0.17–7.00)	0.690	2.24 (1.17–4.28)	0.171
African	2	362/519	1.02 (0.81–1.28)	0.619	1.17 (0.87–1.58)	0.290	0.65 (0.31–1.34)	0.542	1.11 (0.84–1.46)	0.387
Mixed	2	982/2026	1.10 (0.97–1.26)	0.286	1.09 (0.92–1.29)	0.407	1.22 (0.92–1.62)	0.363	1.11 (0.95–1.31)	0.316
Sources of cases
Sporadic	13	4043/5683	1.14 (1.01–1.28)c	0.007	1.25 (1.07–1.47)c	0.008	1.06 (0.88–1.28)	0.345	1.23 (1.05–1.44)c	0.005
Familial	6	1433/1589	1.14 (1.01–1.28)	0.525	1.16 (0.99–1.36)	0.708	1.26 (0.90–1.77)	0.304	1.18 (1.01–1.38)	0.727

Abbreviations: CI, confidence interval; ELAC2, elaC homolog-2; OR, odds ratio.

^aNumber of comparisons.

^bP-value of Q-test for heterogeneity test.

^cA random-effects model was used when P-value for heterogeneity test was <0.05; otherwise, a fixed-effects model was used.